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Epilepsy patients treated with vigabatrin may develop symptomatic or asymptomatic concentric visual field constriction due
to GABA-associated retinal dysfunction. The prevalence and course of this side effect are not established yet; in previously
reported adult patients the visual disturbances seem to be irreversible. We present two patients with a significant improvement
of visual field constriction and retinal function after the discontinuation of vigabatrin. These findings suggest that vigabatrin-
associated retinal changes are at least partly reversible in some patients, and that these patients may benefit significantly from
a withdrawal of vigabatrin. Larger scale clinical studies are needed to identify predictive factors both for the occurrence and
reversibility of vigabatrin-associated visual field defects.
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INTRODUCTION
Since Eke et al’s first report of severe symptomatic
visual field defects in patients taking vigabatrin in
19971, many features of this particular side effect re-
main unclear. The prevalence of clinical and subclini-
cal visual field defects under vigabatrin therapy is not
established yet, and it is not known if these distur-
bances are related to the dose or the duration of vi-
gabatrin exposure, interactions with other antiepilep-
tic drugs, the age of the patient or the type or severity
of epilepsy1–6. To judge the risk versus benefit of a
vigabatrin therapy7, the question about the course of
the visual field defects is crucial. In the vast major-
ity of reported cases the visual field defects failed to
resolve if vigabatrin was stopped. Of the two previ-
ously reported cases with reversibility of visual field
defects after discontinuation of vigabatrin, one was an
atypical unilateral deficit ascribed to an allergic vas-
culitis8, the second occurred in a 10-year-old child9.
We present two adult patients with specific features
of symptomatic vigabatrin-associated visual field de-
fects with a significant recovery after the withdrawal
of the drug. Results of visual field examinations and
electroretinograms (ERG) are provided.
PATIENTS
Patient 1: A 64-year-old man with 43 year history
of complex partial seizures had been treated with vi-
gabatrin 1500 mg/day in addition to his long-standing
therapy with carbamazepine 800 mg/day. Two years
after starting vigabatrin the patient noted gradual non-
specific visual disturbances. Ophthalmological assess-
ment showed a bilateral concentric constriction of the
visual fields which progressed further over the next
20 months until vigabatrin was stopped (Fig. 1a). ERG
demonstrated bilateral increased a-wave latency to
bright light flash (mixed rod-con response), unrecord-
able oscillatory potentials, abnormal phase 30 Hz
flicker response and subnormal pattern ERG, indica-
tive of generalized cone dysfunction in both eyes. The
light rise of the electrooculogram was also subnormal
bilaterally.
Ophthalmological assessments one and six months
after vigabatrin was discontinued revealed a bilateral
significant improvement of the visual field defect and
the ERG (Fig. 1b).
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Fig. 1: (a) Goldman visual fields of patient 1 before vigabatrin therapy was stopped. (b) Visual fields showed an improvement six
months after vigabatrin was stopped. Presented are the results of the left eye, those of the right eye are similar.
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Fig. 2: (a) Goldman visual fields of patient 2 after seven and a half years of vigabatrin therapy. (b) Visual fields of patient 2 four
weeks after vigabatrin was stopped. Presented are the results of the left eye, those of the right eye are similar.
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Patient 2: A 37-year-old man with complex par-
tial seizures since age 14 had been treated with
up to 3500 mg vigabatrin in addition to his stan-
dard antiepileptic medication consisting of phenytoin,
clobazam and felbamate. Seven years after vigaba-
trin was started ophthalmological assessment for in-
termittent peri-orbital pain revealed marked bilateral
symmetrical visual field constriction (Fig. 2a). ERG
abnormalities included unrecordable oscillatory po-
tentials and borderline abnormal responses to 30 Hz
white stimulation. These findings improved signifi-
cantly within four weeks of stopping the drug six
month after the first examination (Fig. 2b).
DISCUSSION
Concentrically constricted visual fields are an un-
common finding in the general population and in
epilepsy patients treated with standard antiepileptic
drugs, but occur in as many as 40% of epilepsy pa-
tients treated with vigabatrin monotherapy6. The two
presented cases showed the typical clinical features
of vigabatrin-related retinal dysfunction as described
in previous reports1. The ERG revealed a preferential
cone system dysfunction and reduced response of the
highly GABAergic amacrine cells as reported earlier
by Krauss et al.10. The rapid recovery of the visual
fields after the discontinuation of vigabatrin confirms
a primary role of the drug in the pathogenesis of retinal
dysfunction. Vigabatrin seems to have the potential to
damage selectively retinal GABAergic cells, presum-
ably by the high levels of GABA resulting from the
inhibition of GABA transaminase. It remains unclear,
however, why the majority of patients remain free of
symptoms, why some patients develop irreversible,
and others reversible visual impairment. The findings
in patient 2 suggest that visual field defects can be re-
versible in adult patients even after a vigabatrin expo-
sure for several years with a relatively high dose.
These case-reports indicate that some patients with
symptomatic visual defects may benefit significantly
from a withdrawal of vigabatrin. In other epilepsy pa-
tients, namely with subclinical or mild visual field de-
fects and a good seizure control, risks from uncon-
trolled seizures may out-weight risks of persistent reti-
nal damage. In some of these patients, a reduced dose
may slow down or stop the progress of the visual com-
plications4. Further research is required to: (1) deter-
mine the prevalence and course of retinal dysfunc-
tion associated with vigabatrin therapy, and (2) clarify
which factors determine the retinal vulnerability and
the reversibility of symptoms.
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